

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058321 A1

(51) International Patent Classification⁷: **A61K 31/44**,
C07D 213/04, A61P 1/04, C07K 14/705

(21) International Application Number:
PCT/SE2004/001819

(22) International Filing Date: 7 December 2004 (07.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0303419-6 17 December 2003 (17.12.2003) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LARSSON, Håkan** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LEHMANN, Anders** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LINDSTRÖM, Erik** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF METABOTROPIC GLUTAMATE RECEPTOR 5 (mGluR5) ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS.

(57) Abstract: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of functional gastrointestinal disorders, such as functional dyspepsia.

WO 2005/058321 A1